3-(furan-2-oyl)-8-methoxy-2H-chromene-2-thione | 1263317-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(furan-2-oyl)-8-methoxy-2H-chromene-2-thione
• 英文别名: Furan-2-yl-(8-methoxy-2-sulfanylidenechromen-3-yl)methanone
• CAS: 1263317-21-0
• 化学式: C₁₅H₁₀O₄S
• 分子量: 286.308
• InChiKey: XTZHTCXQLIPKOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-乙酰基呋喃 在 indium(III) chloride 、 sodium hydride 、 尿素 作用下， 以 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(furan-2-oyl)-8-methoxy-2H-chromene-2-thione
  参考文献：
  名称：

  Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues

  摘要：

  Leishmaniases are an epidemic in various countries, and the parasite is developing resistance against available drugs. Thus, development of new drugs against Leishmania is an open area of investigation for synthetic organic chemists. To meet this challenge, a series of chromene-2-thione derivatives have been synthesized and docked into the active site of trypanothione reductase (TryR) enzyme required for redox balance of the parasite. These were screened on promastigote, axenic amastigote, and intracellular amastigote stages of Leishmania donovani and found to show high levels of antileishmanial activity together with minimal toxicity to human peripheral blood mononuclear cells. Compounds 3b and 3k were found to be the most active among the tested compounds. Although the compounds show moderate antileishmanial activity, they identify a chemical space to design and develop drugs based on these chromene-2-thione derivatives against the Leishmania parasite.

  DOI：

  10.1021/ml200280r

文献信息

• Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues
  作者：Rajiv Kumar Verma、Vijay Kumar Prajapati、Girijesh Kumar Verma、Deblina Chakraborty、Shyam Sundar、Madhukar Rai、Vikash Kumar Dubey、Maya Shankar Singh

  DOI：10.1021/ml200280r

  日期：2012.3.8

  Leishmaniases are an epidemic in various countries, and the parasite is developing resistance against available drugs. Thus, development of new drugs against Leishmania is an open area of investigation for synthetic organic chemists. To meet this challenge, a series of chromene-2-thione derivatives have been synthesized and docked into the active site of trypanothione reductase (TryR) enzyme required for redox balance of the parasite. These were screened on promastigote, axenic amastigote, and intracellular amastigote stages of Leishmania donovani and found to show high levels of antileishmanial activity together with minimal toxicity to human peripheral blood mononuclear cells. Compounds 3b and 3k were found to be the most active among the tested compounds. Although the compounds show moderate antileishmanial activity, they identify a chemical space to design and develop drugs based on these chromene-2-thione derivatives against the Leishmania parasite.